Skip to Content

BioAlliance Pharma presents preclinical results for its AMEP biotherapy in the treatment of invasive melanoma supporting ongoing phase I clinical trial

13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)




(Washington DC, May 17- 22, 2010)




PARIS--(BUSINESS WIRE)--May 25, 2010 - Regulatory News:




BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, has presented efficacy, safety and biodistribution results on its new biotherapy AMEP™ for advanced and metastatic melanoma at the 13th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in Washington, DC (May 17 – 22, 2010).




The AMEP™ biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins) involved in tumor growth and in tumor angiogenesis.




The results presented at the ASGCT demonstrated regulatory preclinical efficacy and safety:








  • Efficacy studies demonstrated that AMEPTM administration in human melanoma xenograft models induced a higher tumor growth inhibition than with Temozolomide, the standard chemotherapy used in metastatic melanoma treatment ;

  • Safety and biodistribution studies showed a good overall tolerance with AMEP™ and a progressive elimination from tissues without accumulation.





Based on these results, AMEP™ phase I clinical trial has been initiated for the treatment of advanced and metastatic melanoma in France, Denmark and Slovenia.




BioAlliance has been granted ‚¬6.4 million from OSEO (the French state innovation agency) which finances technological breakthrough projects.




About the American Society of Gene & Cell Therapy (ASGCT)




The ASGCT is a professional non-profit medical and scientific organization dedicated to the understanding, development and application of genetic and cellular therapies and the promotion of professional and public education in the field. ASGCT includes researchers, clinicians, and other professionals from around the world dedicated to discovering and developing new genetic and cellular therapies.




About BioAlliance Pharma




As a preferred partner for hospital-based specialists, BioAlliance Pharma is a company which develops innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs.




BioAlliance Pharma has developed an advanced product portfolio:




Loramyc® (Oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries and in the United States




Setofilm® (Prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries




Acyclovir Lauriad® (Labialis herpes): Positive phase III final results




Fentanyl Lauriad® (Chronic cancer pain): Positive preliminary Phase I results




AMEPTM (Invasive melanoma): Phase I




Clonidine Lauriad® (Mucositis): Phase II




Doxorubicine Transdrug® (Liver cancer): Phase II




For more information, visit the BioAlliance Pharma web site at








This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.




For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2008 Reference Document filed with the AMF on April 7, 2009, which is available on the AMF website ( or on BioAlliance Pharma SA's website (







Contact: BioAlliance Pharma SA

Dominique Costantini, +33 1 45 58 76 01

President and CEO


Nicolas Fellmann, +33 1 45 58 71 00




Caroline Carmagnol, +33 6 64 18 99 59





Posted: June 2010